<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34006695</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1881-6096</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Brain and nerve = Shinkei kenkyu no shinpo</Title>
          <ISOAbbreviation>Brain Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Immune-Mediated Cerebellar Ataxias].</ArticleTitle>
        <Pagination>
          <StartPage>611</StartPage>
          <EndPage>619</EndPage>
          <MedlinePgn>611-619</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.11477/mf.1416201805</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune mechanisms insult the cerebellum, resulting in the development of cerebellar ataxias (CAs). These immune-mediated cerebellar ataxias (IMCAs) include gluten ataxia, postinfectious cerebellitis, paraneoplastic cerebellar degeneration (PCD), antiglutamate decarboxylase 65 antibody-associated CA (anti-GAD ataxia), and primary autoimmune cerebellar ataxia (PACA). Cell-mediated mechanisms are assumed to be involved in PCD, whereas accumulating evidence shows that anti-GAD antibodies decrease the amount of GABA released which leads to functional synaptic deficits. The therapeutic benefits of immunotherapies vary depending on the etiology of the disease. Early intervention is recommended while the cerebellar reserve can be preserved.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mitoma</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Education, Tokyo Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>jpn</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Brain Nerve</MedlineTA>
        <NlmUniqueID>101299709</NlmUniqueID>
        <ISSNLinking>1881-6096</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8002-80-0</RegistryNumber>
          <NameOfSubstance UI="D005983">Glutens</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002524" MajorTopicYN="Y">Cerebellar Ataxia</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005983" MajorTopicYN="N">Glutens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34006695</ArticleId>
        <ArticleId IdType="doi">10.11477/mf.1416201805</ArticleId>
        <ArticleId IdType="pii">1416201805</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34006695</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1881-6096</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Brain and nerve = Shinkei kenkyu no shinpo</Title>
          <ISOAbbreviation>Brain Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Immune-Mediated Cerebellar Ataxias].</ArticleTitle>
        <Pagination>
          <StartPage>611</StartPage>
          <EndPage>619</EndPage>
          <MedlinePgn>611-619</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.11477/mf.1416201805</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune mechanisms insult the cerebellum, resulting in the development of cerebellar ataxias (CAs). These immune-mediated cerebellar ataxias (IMCAs) include gluten ataxia, postinfectious cerebellitis, paraneoplastic cerebellar degeneration (PCD), antiglutamate decarboxylase 65 antibody-associated CA (anti-GAD ataxia), and primary autoimmune cerebellar ataxia (PACA). Cell-mediated mechanisms are assumed to be involved in PCD, whereas accumulating evidence shows that anti-GAD antibodies decrease the amount of GABA released which leads to functional synaptic deficits. The therapeutic benefits of immunotherapies vary depending on the etiology of the disease. Early intervention is recommended while the cerebellar reserve can be preserved.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mitoma</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Education, Tokyo Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>jpn</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Brain Nerve</MedlineTA>
        <NlmUniqueID>101299709</NlmUniqueID>
        <ISSNLinking>1881-6096</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8002-80-0</RegistryNumber>
          <NameOfSubstance UI="D005983">Glutens</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002524" MajorTopicYN="Y">Cerebellar Ataxia</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005983" MajorTopicYN="N">Glutens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34006695</ArticleId>
        <ArticleId IdType="doi">10.11477/mf.1416201805</ArticleId>
        <ArticleId IdType="pii">1416201805</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
